Sanford C. Bernstein Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,070.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by Sanford C. Bernstein from $1,110.00 to $1,070.00 in a report published on Tuesday morning,Benzinga reports. Sanford C. Bernstein currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on the company. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Bank of America reissued an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,044.48.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $733.59 on Tuesday. Regeneron Pharmaceuticals has a 1 year low of $693.00 and a 1 year high of $1,211.20. The company has a fifty day simple moving average of $754.37 and a 200 day simple moving average of $965.13. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market cap of $80.61 billion, a P/E ratio of 18.15, a P/E/G ratio of 2.19 and a beta of 0.10.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sachetta LLC boosted its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.